Emyria
Leederville, Australia
We are on track to become world-leaders in a promising new mental healthcare market, through our efforts to test MDMA and psilocybin for the treatment of conditions like post traumatic stress disorder (PTSD) and depression. We are also developing novel MDMA-like compounds and exploring their potential in select neurological conditions like Parkinson’s disease, and more. The societal and economic motivation to address mental health is real. Over 2 in 5 Australians experience a mental disorder at some time in their life. 1 in 5 Australians had a mental disorder in the past 12 months. Demand is unprecedented but, in Australia right now, 1 in 3 psychologists have closed books. We need entirely new solutions.
Only accessible to MedStartr community members.
Join nowCompany Info
- Founded
- 2018
- Website
- emyria.com/
Categories
Only accessible to MedStartr community members.
Join nowWhat do you think of Emyria?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now